Mylan nabs Indian OK for Agila buy; Sanofi chief takes over at EFPIA;

 @FiercePharma: Sanofi, Novartis, Glaxo said to be circling India's Elder Pharma. Private equity, too. News | Follow @FiercePharma

 @EricPFierce: Ranbaxy gets some support from India's Supreme Court as company faces down concerns there. Item | Follow @EricPFierce

 @CarlyHFierce: Proxy fight heating up at Vivus...First Manhattan announces search for new CEO candidates. Report | Follow @CarlyHFierce

> Mylan ($MYL) won Indian regulatory approval for its buyout of the injectables drugmaker Agila Specialties. Report

> Sanofi ($SNY) CEO Christopher Viebacher has taken over as president of the European Federation of Pharmaceutical Industries and Associations (EFPIA). Report

> Avanir Pharmaceuticals ($AVNR) won approval from the European Commission for its drug Nuedexta, a treatment for pseudobulbar affect, a condition characterized by extraordinary emotional outbursts. Report

> Hungary's Richter snapped up a manufacturing and marketing license to Acrux's estradiol spray for menopause symptoms in a deal worth up to $3.6 million. Report

> Aspirin's benefit in thwarting colon cancer doesn't extend to tumors with a mutation in the BRAF gene, a study found. Report

> Taking medicines containing caffeine was linked to a double or even triple risk of stroke, a new study found. Report

Medical Device News

 @FierceMedDev: Activaero readies for hoped-for EU launch of its first drug/device treatment. Editor's corner | Follow @FierceMedDev

 @DamianFierce: Delcath is axing 20% of its workforce after the FDA frowned upon its cancer-treating device. News | Follow @DamianFierce

> Thermo pours $9.5M into Chinese R&D shop. More

> Navidea raises $25M to market Lymphoseek. Item

> Intuitive hit with FDA warning over da Vinci reports. Story

> NanoString craves $54M in scaled-back IPO. Report

Biotech News

 @FierceBiotech: Where were the breakthrough drugs for diabetes at ADA 2013? Editor's corner | Follow @FierceBiotech

 @JohnCFierce: Have to wonder how PTC's IPO will come out as questions are raised about its lead obsession, um, program. Article | Follow @JohnCFierce

 @RyanMFierce: Verastem launching a PhI for second FAK inhibitor in pipeline. | Follow @RyanMFierce

 @EmilyMFierce: And back to biotech... Genetic biomarkers could help tailor breast cancer therapies. Article | Follow @EmilyMFierce

> Roche, AstraZeneca join forces on precompetitive R&D initiative. More

> Delcath slashes U.S. staff by 20% after FDA-panel disaster. Story

Biomarkers News

> Arizona's TGen and Ventana Medical Systems partner to find cancer biomarkers. News

> New diagnostic IDs patients unlikely to benefit from chemoradiation. Item

> Traumatic brain injury biomarker company raises $6M for diagnostic. Item

> HPV antibodies point researchers to high risk for oral cancer. Story

> Brain scan may provide biomarker guideposts to ideal depression treatment. Article

Drug Delivery News

 @MichaelGFierce: Trending right now at FierceDrugDelivery: Insulin delivery devices at ADA 2013. Roundup | Follow @MichaelGFierce

> Acorda reports positive data for epilepsy nasal spray. Item

> Alnylam posts positive preclinical RNAi delivery results for fatal conditions. Article

> Microbubbles for imaging offer targeted drug-delivery approach. More

> Peptide-coated nano-gold shows cancer-fighting promise. Report

And Finally... Expensive running shoes don't prevent injuries, a study found. Report

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.